These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30951811)

  • 1. The problem of poly-pharmacotherapy in patients on a mephedrone binge.
    Ordak M; Nasierowski T; Muszynska E
    Pharmacol Res; 2019 May; 143():204. PubMed ID: 30951811
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of synthetic psychoactive cathinones and amphetamine stimulants on the gut microbiome in mice.
    Angoa-Pérez M; Zagorac B; Winters AD; Greenberg JM; Ahmad M; Theis KR; Kuhn DM
    PLoS One; 2020; 15(1):e0227774. PubMed ID: 31978078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mephedrone].
    Bertrand X; Gensburger M; Steckx E
    Rev Med Liege; 2011 Oct; 66(10):540-4. PubMed ID: 22141261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential dangers of mephedrone in people with diabetes: a case report.
    Wong ML; Holt RI
    Drug Test Anal; 2011; 3(7-8):464-5. PubMed ID: 21755609
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel psychoactive substances: a novel clinical challenge.
    Smith CD; Williams M; Shaikh M
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23964049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
    Tretter F
    Nervenarzt; 1997 Nov; 68(11):922-3. PubMed ID: 9732739
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone.
    den Hollander B; Rozov S; Linden AM; Uusi-Oukari M; Ojanperä I; Korpi ER
    Pharmacol Biochem Behav; 2013 Jan; 103(3):501-9. PubMed ID: 23099177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mephedrone related fatalities: a review.
    Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3777-90. PubMed ID: 26502870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mephedrone and other cathinones.
    Zawilska JB
    Curr Opin Psychiatry; 2014 Jul; 27(4):256-62. PubMed ID: 24852055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deconstructing Designer Drugs.
    Sellers EM
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heavy metal and organic contaminants associated with illicit methamphetamine production.
    Burton BT
    NIDA Res Monogr; 1991; 115():47-59. PubMed ID: 1758482
    [No Abstract]   [Full Text] [Related]  

  • 13. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change.
    Dargan PI; Albert S; Wood DM
    QJM; 2010 Nov; 103(11):875-9. PubMed ID: 20675396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UK places generic ban on mephedrone drug family.
    Morris K
    Lancet; 2010 Apr; 375(9723):1333-4. PubMed ID: 20405534
    [No Abstract]   [Full Text] [Related]  

  • 15. 'Heads held high': an exploratory study of legal highs in pre-legislation Ireland.
    Van Hout MC; Brennan R
    J Ethn Subst Abuse; 2011; 10(3):256-72. PubMed ID: 21888502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synthetic Drugs - An Overview of Important and Newly Emerging Substances].
    Betzler F; Heinz A; Köhler S
    Fortschr Neurol Psychiatr; 2016 Nov; 84(11):690-698. PubMed ID: 27846654
    [No Abstract]   [Full Text] [Related]  

  • 17. [The phenomenon of drug change in the interviews with injecting drug users].
    Rácz J; Csák R; Faragó R; Vadász V
    Psychiatr Hung; 2012; 27(1):29-47. PubMed ID: 22493147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply.
    McElrath K; O'Neill C
    Int J Drug Policy; 2011 Mar; 22(2):120-7. PubMed ID: 21242082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone.
    Wood DM; Greene SL; Dargan PI
    Emerg Med J; 2011 Apr; 28(4):280-2. PubMed ID: 20581379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimisation of methadone treatment in a group of patients on a mephedrone binge and dependent on many psychoactive substances.
    Ordak M; Nasierowski T; Muszynska E; Bujalska-Zadrozny M
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):38-42. PubMed ID: 31663415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.